tbuckley/cabot-search huggingface dataset:
Bee venom phospholipase A2 ameliorates amyloidogenesis and neuroinflammation through inhibition of signal transducer and activator of transcription-3 pathway in Tg2576 mice
Authors: Hyeon Joo Ham, Sang-Bae Han, Jaesuk Yun, In Jun Yeo, Young Wan Ham, Se Hyun Kim, Pil-Hoon Park, Dong-Young Choi, Jin Tae Hong
Journal: Translational Neurodegeneration (2019)

Abstract Background Neuroinflammation and accumulation of β-amyloid (Aβ) play a significant role in the onset and progression of Alzheimer’s disease (AD). Our previous study demonstrated that signal transducer and activator of transcription-3 (STAT3) plays a major role in neuroinflammation and amyloidogenesis. Methods In the present study, we investigated the inhibitory effect of bee venom phospholipase A2 (bvPLA2) on memory deficiency in Tg2576 mice, which demonstrate genetic characteristics of AD and the mechanism of its action at the cellular and animal level. For in vivo study, we examined the effect of bvPLA2 on improving memory by conducting several behavioral tests with the administration of bvPLA2 (1 mg/kg) to Tg2576 mice. For in vitro study, we examined the effect of bvPLA2 on amyloidogenesis and neuroinflammation by treating bvPLA2 on LPS-activated BV2 cells. Results We found that bvPLA2 alleviated memory impairment in Tg2576 mice, as demonstrated in the behavioral tests assessing memory. In the bvPLA2-treated group, Aβ, amyloid precursor protein (APP), and β-secretase 1 (BACE1) levels and β-secretase activity were significantly decreased. Expression of pro-inflammatory cytokines and inflammation-related proteins decreased in the brain of bvPLA2-treated group, whereas anti-inflammatory cytokines increased. In addition, bvPLA2 reduced STAT3 phosphorylation in the brains of the bvPLA2-treated group. At the cellular level, bvPLA2 inhibits production of nitric oxide, pro-inflammatory cytokines, and inflammation-related proteins including p-STAT3. Additionally, bvPLA2 inhibits the production of Aβ in cultured BV-2 cells. Results from the docking experiment, pull-down assay, and the luciferase assay show that bvPLA2 directly binds STAT3 and, thus, regulates gene expression levels. Moreover, when the STAT3 inhibitor and bvPLA2 were administered together, the anti-amyloidogenic and anti-inflammatory effects were further enhanced than when they were administered alone. Conclusion These results suggest that bvPLA2 could restore memory by inhibiting the accumulation of Aβ and inflammatory responses via blockage of STAT3 activity.
Flu vaccine: most stock to arrive by November, but some orders will be delayed
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Most of the vaccine stock ordered for the coming flu season will arrive before 31 October (the current date for the UK to leave the European Union), but some general practices and pharmacists will face delays.

Sanofi Pasteur, which is supplying the quadrivalent vaccine (QIVc), will deliver a third of its deliveries after 31 October. To try to prevent any flu vaccine shortages, England’s health secretary, Matt Hancock, has ordered an additional 400 000 doses of quadrivalent vaccine, which will arrive before 31 October.

For the 2019-20 flu season 25 million people will be able to get vaccinated, one million more than last …
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Authors: D. Moro-Sibilot, N. Cozic, M. Pérol, J. Mazières, J. Otto, P.J. Souquet, R. Bahleda, M. Wislez, G. Zalcman, S.D. Guibert, F. Barlési, B. Mennecier, I. Monnet, R. Sabatier, S. Bota, C. Dubos, V. Verriele, V. Haddad, G. Ferretti, A. Cortot, F. De Fraipont, M. Jimenez, N. Hoog-Labouret, G. Vassal
Journal: Annals of Oncology (2019)
Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia
Authors: Amanda Kofides, Maria Demos, Nickolas Tsakmaklis, Lian Xu, Xia Liu, Christopher Patterson, Maria Luisa Guerrera, Manit Munshi, Guang Yang, Jiaji G Chen, Cristina Jimenez, Gloria G Chan, Joshua Gustine, Jorge J. Castillo, Steven P Treon, Zachary R Hunter
Journal: Blood (2018)
Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Authors: C. Mercier, C. Billiet, M. Strijbos, T. Van den Mooter, F. Vandaele, I. Joye, A. Buys, C. Rypens, S. Oeyen, S.J. Van Laere, P. Vermeulen, P. Dirix
Journal: Annals of Oncology (2019)
Abstract 16999: Can CCTA Enhance Our Understanding of Coronary Artery Disease in South Asian Population?
Authors: Amir Ahmadi, Jonathon Leipsic, Carolyn Taylor, Brett Heilbron, Krishnan Ramanathan
Journal: Circulation (2013)

Background: Compared to age-matched Caucasians, South Asians (SA) have a higher prevelance of coronary artery disease (CAD) related morbidity and mortality. We sought to evaluate the use of coronar...
Defining the immunologic phenotypes and their prognostic impacts on head and neck squamous cell cancer (HNSCC).
Authors: HyeRyun Kim, Su Jin Heo, Jee Hyung Kim, Kyoung Ho Pyo, Sun Och Yoon, Byoung Chul Cho
Journal: Journal of Clinical Oncology (2016)

6055 Background: To investigate the frequency and distributing patterns of programmed death-ligand 1 (PD-L1), other immune checkpoints (ICP) and their prognostic impacts in resected HNSCC. Methods: PD-L1 expression and its pattern on tumor cells (TC) and tumor-infiltrating immune cells (IC) were investigated, using SP142 assay, in micro-arrayed tumors from 402 HNSCC. PD-L1 on TC and IC can be categorized into 4 groups according to their percentage; TC0 or IC0, < 1%; TC1 or IC1, ≥ 1% and < 5%; TC2 or IC2, ≥ 5% and < 50%; TC3 or IC3, ≥ 50%. PD-L1 positivity was defined as ≥ 5% of TC or IC by immunohistochemistry. Tumor infiltrating lymphocytes (TIL) and their various ICP, i.e. programmed death-1 (PD-1), lymphocyte-activation gene-3 (LAG-3), and inducible T-cell co-stimulator (ICOS), were evaluated. The densities of TIL and various ICP were semi-quantitatively scored, and positivity was defined as higher than the median value of each marker. The association between various immune markers, recurrence-free survival (RFS) and overall survival (OS) were analyzed. Results: The predominant primary sites were oral cavity (50.7%) and oropharynx (30.3%). The proportions of stage were 28.9% stage I, 10.7% stage II, 18.4% stage III, and 42.0% stage IVA/B. In a Cox proportional hazard model adjusted for age, gender, smoking, stage and HPV status, high PD-L1 expression on IC was an independent prognostic factor for better RFS and OS (RFS: adjusted hazard ratio [AHR], 0.49; P = .0007; OS: AHR, 0.37;P = .04). High CD3+ or CD8+ TIL density, expression of FOXP3, and PD-1 in TIL were independently associated with better prognosis. HNSCC is further characterized by tumors that express PD-L1 exclusively on TC or IC. Notably, TC3 and IC3 represent distinct populations with < 1% overlap, suggesting that PD-L1 might be regulated by the distinct mechanisms in TC and IC subsets. IC3 exhibit higher CD8+TIL density compared to TC3, suggesting that PD-L1 on IC is regulated by adaptive mechanisms and reflects pre-existing immunity. Conclusions: PD-L1 on IC is independent predictors of OS in resected HNSCC. This highlights the importance of comprehensive assessment on both TC and IC. Exploratory analysis of tumor gene expression will be presented.
Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
Authors: M. Kudo, P.R. Galle, K. Motomura, E. Assenat, P. Merle, G. Brandi, B. Daniele, T. Okusaka, J. Tomasek, C. Borg, V. Zagonel, M. Morimoto, M. Pracht, R.S. Finn, J. Llovet, G. Homma, M.-H. Jen, K. Shinozaki, R. Yoshikawa, A.X. Zhu
Journal: Annals of Oncology (2019)
Early palliative care interventions in patients with hematologic malignancies prior to hematopoietic cell transplantation.
Authors: M.Ahsan Alamgir, Sijin Wen, Michael D. Craig, Sandra L. Pedraza
Journal: Journal of Clinical Oncology (2017)

e21634 Background: Early palliative care (EPC) interventions have been endorsed by multiple medical societies, mostly for solid tumors but not for hematological malignancies. Patients undergoing hematopoietic stem cell transplantation (HSCT) suffer significant physical and emotional distress affecting negatively their quality of life (QOL). They also receive more aggressive end-of-life interventions than other cancer patients. Few studies have shown the impact of EPC in the pre-transplant phase on post transplant morbidity and mortality. Methods: 53 patients undergoing HSCT were evaluated on the supportive care clinic for symptom and needs assessment using the Edmonton symptom assessment scale (ESAS) to evaluate symptom burden prior to transplant. Consecutive palliative care visits were offered to patients. We also evaluated whether the supportive care clinic (SCC) visits made a difference on hospitalization rate and mortality comparing this group with 108 patient who did not undergo evaluation. Kaplan-Meier method and log-rank test were used in the survival analysis and Fisher’s exact test was used in the data analysis for categorical variables. Results: The most common symptoms reported by patients included: fatigue (4.4), sleep problems (3.7), pain (2.8), anxiety (2.8), well-being (2.7), and drowsiness (2.3). 26% (14) of the patients were followed in the SCC at 3 months. The most common symptoms at that time included fatigue (5.1), pain (4), drowsiness (3.6), sleep problems (3.1), well-being (2.9), and appetite (2.4). Overall mortality for the whole group was 24%. 28% for the palliative care group and 21% for the control group. Odds Ratio for mortality at 3 and 6 months were not significantly different between groups. Differences in hospital admissions were also not statistically significant. Conclusions: EPC in HSCT patients is feasible and may help with symptom detection and control. No effect on mortality or hospital admission rates was found on this study on patients referred for EPC interventions. Prospective studies are needed to clearly define the role of EPC in HSCT patients.
Tobacco smoking is associated with the immune suppressive microenvironment in head and neck squamous cell carcinoma (HNSCC)
Authors: C.H. Chung, J.V. de la Iglesia, X. Wang, F. Song, R. Chaudhary, J. Masannat, J. Conejo-Garcia, J. Hernandez-Prera, R. Slebos
Journal: Annals of Oncology (2019)
Long-Term Outcomes of Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression
Authors: Andrea L. Crowell, Patricio Riva-Posse, Paul E. Holtzheimer, Steven J. Garlow, Mary E. Kelley, Robert E. Gross, Lydia Denison, Sinead Quinn, Helen S. Mayberg
Journal: American Journal of Psychiatry (2019)

Deep brain stimulation of the subcallosal cingulate (SCC DBS) has been studied as a potential treatment for severe and refractory major depressive disorder since 2005. The authors used an open-label, long-term follow-up design to examine participants enrolled in a clinical trial of SCC DBS for treatment-resistant depression.Long-term outcome data were collected for 28 patients (20 with major depressive disorder and seven with bipolar II disorder; one patient in the major depression subgroup was later reclassified as having bipolar II disorder) receiving SCC DBS for 4-8 years.Response and remission rates were maintained at ≥50% and ≥30%, respectively, through years 2-8 of the follow-up period. Three-quarters of all participants met the treatment-response criterion for more than half of their duration of participation in the study, with 21% of all patients demonstrating continuous response to treatment from the first year onward. Of 28 participants, 14 completed ≥8 years of follow-up, 11 completed ≥4 years, and three dropped out before 8 years. The procedure itself was generally safe and well tolerated, and there were no side effects of acute or chronic stimulation. The rate of medical or surgical complications was consistent with the rate observed in studies of DBS for other indications. There were no suicides.In >8 years of observation, most participants experienced a robust and sustained antidepressant response to SCC DBS.
Editor's Note: <i>mda-9</i>/Syntenin: A Positive Regulator of Melanoma Metastasis
Authors: Habib Boukerche, Zao-Zhong Su, Luni Emdad, Patrick Baril, Brigitte Balme, Luc Thomas, Aaron Randolph, Kristoffer Valerie, Devanand Sarkar, Paul B. Fisher
Journal: Cancer Research (2019)

The editors were made aware of several concerns pertaining to Figs. 1, 2, and 4 in [this article][1] ([1][2]). The Western blot images in Figs. 1 and 4 were prepared based on the acceptable standards at the time of submission. In Fig. 2C, duplicate migration/invasion assay images were used to
Psychological distress in myelodysplastic syndromes.
Authors: Jaxon Vallely, Jesse D Troy, Susan C. Locke, Thomas William LeBlanc
Journal: Journal of Clinical Oncology (2018)

e19027 Background: Patients with myelodysplastic syndromes (MDS) experience distress associated with physical, emotional and social problems. However, differences in sources of distress across the highly variable prognostic groups in MDS have not been described. Methods: We reviewed charts of adult MDS patients visiting the Duke Cancer Institute (DCI) from July 2013-September 2015. Extracted data included the National Comprehensive Cancer Network Distress Thermometer (DT) and Problem List (PL), which are used to assess patient-reported distress in all DCI clinics. The DT is a validated, patient-reported screening tool that solicits distress during the past week on a scale from 0 (no distress) to 10 (extreme distress). Patients may also select any of 39 problems contributing to their distress, grouped into 5 domains: Practical, Family, Emotional, Physical, and Spiritual/Religious. Patients were classified as having Low or Intermediate/High risk MDS using the Revised International Prognostic Scoring System or the World Health Organization Prognostic Scoring System, depending on data available in the chart. Mean distress was compared by MDS risk strata using Generalized Estimating Equations, and contingency tables were used to compare ever-reported PL items across risk strata. Results: A total of 376 DT and PL were abstracted for 110 patients (75% white, 68% male, median age = 69 years at diagnosis). Fifty-nine patients had Low Risk disease and 51 were Intermediate/High risk. Mean distress did not differ between Low (mean = 2.5, 95% CI: 1.8, 3.1) and Intermediate/High Risk (mean = 3.1, 95% CI: 2.3, 3.8) (P = 0.25) but sources of distress differed by risk strata. Namely, distress due to Treatment Decisions was more likely in Intermediate/High Risk patients (37%) compared with Low Risk (17%) (P = 0.02). However, distress due to Indigestion was more common in Low Risk (24%) than Intermediate/High Risk patients (8%) (P = 0.04). Fatigue was the most prevalent source of distress in both groups: 68% of Low Risk and 75% of Intermediate/High Risk (P = 0.53). Conclusions: Sources of distress, but not overall distress level, vary across MDS risk strata. This suggests that MDS patients at different stages of illness may have different psychosocial and supportive care needs.
ACTR-58. TREATMENT OUTCOMES OF STEREOTACTIC RADIOTHERAPY COMBINED WITH BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA PATIENTS
Authors: Yukihiko Sonoda, Ken-ichiro Matsuda
Journal: Neuro-Oncology (2018)

The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. We performed a retrospective analysis of 11 patients with recurrent glioblastoma treated with stereotactic radiotherapy (25Gy/5fr) followed by 200 mg/m2 of Bevacizumab every three weeks. Overall survival was estimated by the Kaplan-Meier method. The median age of the group was 59 years. Median overall survival from initial diagnosis was 21 months weeks. Median overall survival from recurrence was 11 months. No adverse events (National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or 4) occurred in any patient. CONCLUSION: Stereotactic radiotherapy combined with BEV treatment was found to be safe and effective in recurrent glioblastoma patients.
Most Risk-Stratification Molecular Markers in Acute Myeloid Leukemia (AML) Are Rarely Found in Early Childhood AML in the Middle Eastern Population
Authors: Hala Abalkhail, Hassan El-Solh, Amal Alseraihy, Asim F Belgaumi, Abdullah Al-Jefri, Mouhab Ayas, Ali Al-Ahmari, Fahed Almhareb, Naeem A. Chaudhri, Claudia Ulrike Walter, Mahmoud Aljurf, Maher Albitar
Journal: Blood (2011)
Protein Arginine Methyltransferase 5 Directly Targets and Epigenetically Silences microRNAs miR33b and miR96 to Support Constitutive Cyclin D1 Activity in Non-Hodgkin’s Lymphoma
Authors: Vrajesh Karkhanis, Olivier Elemento, Maurizio Di Liberto, Selina Chen-Kiang, Said Sif, Robert A. Baiocchi
Journal: Blood (2014)
Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Authors: E. Van Cutsem, A. Valderrama, Y.-J. Bang, C. Fuchs, K. Shitara, Y.Y. Janjigian, S. Qin, T. Larson, V. Shankaran, S. Stein, J.M. Norquist, U. Kher, S. Shah, M. Alsina
Journal: Annals of Oncology (2019)
Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Authors: I.H. Um, L. Scott-Hayward, M. MacKenzie, P.H. Tan, R. Kanesvaran, Y. Choudhury, M.-H. Tan, M. O’Donnell, P.D. Caie, G.D. Stewart, D.J. Harrison
Journal: Annals of Oncology (2019)
Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Authors: R. Shah, N. Girard, S.P. Nagar, F. Griesinger, J. Roeper, K. Davis, N. Bakker, B. Thakrar, A. Taylor, J. Feliciano
Journal: Annals of Oncology (2019)
Pathophysiology of Psychogenic Nonepileptic Attacks—Reply
Authors: Benjamin Tolchin, Steve Martino, Lawrence J. Hirsch
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of systemic inflammation with local tumour characteristics and survival in glioma patients
Authors: P. Mir Seyed Nazari, C. Ay, M. Preusser, J. Riedl, C. Marosi, F. Moik, G. Ricken, J.A. Hainfellner, I. Pabinger-Fasching, A.S. Berghoff
Journal: Annals of Oncology (2019)
Acetyl-11-keto-β-boswellic acid attenuates titanium particle-induced osteogenic inhibition via activation of the GSK-3β/β-catenin signaling pathway
Authors: Longbin Xiong, Yu Liu, Feng Zhu, Jiayi Lin, Dongxiang Wen, Zhen Wang, Jiaxiang Bai, Gaoran Ge, Congxin Xu, Ye Gu, Yaozeng Xu, Jun Zhou, Dechun Geng
Journal: Theranostics (2019)

Rationale: Peri-prosthetic osteolysis (PPO) is mainly induced by wear particles and represents the leading cause of implant failure and revision surgery. Previous studies have identified mitigation of wear particle-induced inflammation and bone resorption as the main approaches to treat PPO. Recently, wear particle-induced reduction of bone formation around the prosthesis was identified as a major factor in the development of PPO. Acetyl-11-keto-β-boswellic acid (AKBA), a derivative of frankincense, has been shown to play a potential role in bone metabolism. However, whether AKBA enhances bone formation in wear particle-induced osteolysis remains unknown. In this study, we examined whether AKBA attenuates titanium particle-induced osteogenic reduction. Methods: Titanium particles were used to induce osteolysis in murine calvaria, and micro-CT and histological analyses were used to evaluate the results. Mouse osteoblast cells, MC3T3-E1 were co-cultured with titanium particles to determine their effect on osteoblast formation in vitro. Results: We demonstrated that AKBA treatment significantly inhibited titanium particle-induced osteogenic inhibition by enhancing osteogenesis both in vivo and in vitro. AKBA treatment also enhanced the phosphorylation of GSK-3β, decreased the degradation of β-catenin, and increased the translocation of β-catenin from the cytoplasm to the nucleus. Taken together, these results showed that AKBA treatment attenuated titanium-induced osteogenic inhibition by activating the GSK-3β/β-catenin signaling pathway. Conclusion: These findings suggest that AKBA is a promising new target in the prevention and treatment of PPO.
A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial
Authors: T. Seufferlein, T.J. Ettrich, A. Stein, D. Arnold, G. Prager, S. Kasper, M. Niedermeier, L. Mueller, S. Kubicka, A.-O. König, P. Büchner-Steudel, K. Wille, A. Kestler, A. Hann, L. Perkhofer, A.W. Berger, L. Lausser, H. Kestler
Journal: Annals of Oncology (2019)
Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
Authors: S. Kim, A. Meurisse, M. Stouvenot, M. Jary, T Nguyen Tan Hon, E. Francois, B. Buecher, T. Andre, E. Samalin, F. Boulbair, B. De Bari, H. Almotlak, E. Klajer, F. Calcagno, E. Chatillon, L. Spehner, M. Jacquin, V. Vendrely, D. Vernerey, C. Borg
Journal: Annals of Oncology (2019)